Icumulus

iCumulus is a new-age global fulfilment platform, leading the revolution of e-commerce, turning it into a totally shared & unified global economy. iCumulus connects your business to a network of global logistics providers, creating a unique shared ecosystem with the most competitive shipping rates. Unlike traditional logistics providers, iCumulus scales not by assets, staff or inventory, but by connecting true demand to supply ensuring best consumer experience. Our comprehensive cloud based e-fulfilment platform manages all distributions, purchasing, into store and consumer deliveries at no additional cost. We want our customers to be free to deal with what's important to them - service their customers, allowing them grow sales and reach new markets.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

news image

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

news image

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

news image

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More

INDUSTRIAL IMPACT

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

news image

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More
news image

J&J JUMPING IN ON CORONAVIRUS VAX WORK AS DISEASE CONTINUES ITS SPREAD

FierceBiotech | January 27, 2020

Johnson & Johnson is joining the growing ranks of biopharmas, including the likes of Moderna and Gilead Sciences, in trying to create a speedy vaccine for the coronavirus out of China. Over the weekend, we learned of a wider range and more deaths as the new virus, which appears to have come out of Wuhan, China, is doing what these diseases do best: spread. The causes of death have so far been reported as pneumonia, with other reports suggesting most of these have come from those with underly...

Read More
news image

AVM BIOTECHNOLOGY HIRES EXECUTIVE TEAM FOR ONCOLOGY & COVID-19 CLINICAL TRIALS

AVM Biotechnology | July 09, 2020

Seattle's AVM Biotechnology, an up-and-coming biotech firm whose lead molecule, AVM0703, has received FDA permission to begin clinical trials treating no-option Non-Hodgkin's Lymphoma and is applying to begin trials treating moderate-severely ill COVID-19 patients, announced today the hiring of Janet R. Rea, MSPH, as Chief Operating Officer. As COO, Rea will lead operations and direct regulatory affairs as the company conducts clinical trials and brings AVM0703 to market."I am...

Read More
news image

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More
news image

INDUSTRIAL IMPACT

MERAKRIS AND DEPT. OF VETERANS AFFAIRS SIGN CRADA AGREEMENT – CLINICAL TRIAL FOR DERMACYTE® WOUND CARE PRODUCT TO BEGIN SOON

Merakris Therapeutics | February 09, 2022

Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Department of Veterans Affairs (VA) to test its investigational drug product, Dermacyte® Amniotic Wound Care Liquid. The VA plans to enroll patients, ages 18-75, in a two-part Phase II clinical study to evaluate Merakris’ first in class subcutaneous – or below the skin – injectable wound healing therapy. The study is designe...

Read More